Perspective Therapeutics Stock Today
| CATX Stock | 4.15 0.20 4.60% |
Performance0 of 100
| Odds Of DistressLess than 20
|
Perspective Therapeutics is trading at 4.15 as of the 2nd of December 2024; that is 4.6% down since the beginning of the trading day. The stock's open price was 4.35. Perspective Therapeutics has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Perspective Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of December 2022 and ending today, the 2nd of December 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 10th of November 2005 | Category Healthcare | Classification Health Care |
Perspective Therapeutics is entity of United States. It is traded as Stock on NYSE MKT exchange. The company has 67.59 M outstanding shares of which 8.28 M shares are currently shorted by private and institutional investors with about 10.75 trading days to cover. More on Perspective Therapeutics
Moving against Perspective Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Perspective Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Johan Spoor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Perspective Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Perspective Therapeutics' financial leverage. It provides some insight into what part of Perspective Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Perspective Therapeutics (CATX) is traded on NYSE MKT Exchange in USA. It is located in 2401 Elliott Avenue, Seattle, WA, United States, 98121 and employs 116 people. Perspective Therapeutics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 294.01 M. Perspective Therapeutics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 67.59 M outstanding shares of which 8.28 M shares are currently shorted by private and institutional investors with about 10.75 trading days to cover.
Perspective Therapeutics generates negative cash flow from operations
Check Perspective Therapeutics Probability Of Bankruptcy
Ownership AllocationPerspective Therapeutics owns a total of 67.59 Million outstanding shares. The majority of Perspective Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Perspective Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Perspective Therapeutics. Please pay attention to any change in the institutional holdings of Perspective Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that almost one million two hundred seventy-seven thousand four hundred four invesors are currently shorting Perspective Therapeutics expressing very little confidence in its future performance.
Check Perspective Ownership Details
Perspective Therapeutics Historical Income Statement
Perspective Stock Against Markets
Perspective Therapeutics Corporate Management
| MD MBA | Chief Officer | Profile | |
| Shane Cobb | Executive Operations | Profile | |
| Annie Cheng | Vice Relations | Profile | |
| Mark CPA | Controller, Finance | Profile | |
| Andrew Bright | Executive Brachytherapy | Profile | |
| Michael Schultz | Chief Officer | Profile |
Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.